Human immunodeficiency virus - Diagnosis and Testing Strategies

HIV Testing and Diagnosis Introduction Diagnosing HIV requires a systematic approach using laboratory tests to detect the virus or the body's immune response to it. The diagnosis process combines initial screening tests with confirmatory testing to ensure accuracy, while accounting for the window period—a critical concept that affects test reliability. Understanding Key Diagnostic Markers Before diving into specific tests, it's important to understand what we're actually measuring when diagnosing HIV. CD4+ T Cell Count measures the number of CD4 positive T cells (reported as cells per microliter of blood). This is crucial because CD4+ T cells are a primary target of HIV, and their count directly reflects how severely the virus has compromised the immune system. A normal CD4+ count is typically 500-1,500 cells/µL; lower counts indicate more advanced disease. Viral Load refers to the number of HIV RNA copies present in one milliliter of blood plasma. This measures how actively the virus is replicating in the body. Together, CD4+ count and viral load provide the clearest picture of a person's immune status and disease progression. The Window Period: Why Timing Matters The window period is the time immediately after HIV infection during which the virus is present and actively replicating, but antibodies against HIV have not yet developed. During this window—typically 18 to 45 days—standard antibody detection tests will produce false negative results, making diagnosis more challenging. This is critical: ELISA screening has sensitivity greater than 99%, but this calculation accounts for the window period. Understanding this limitation is essential for interpreting test results and explaining why repeat testing is sometimes necessary. Initial Screening: The Combination Immunoassay The enzyme-linked immunosorbent assay (ELISA) was historically the first-line screening test, and remains important. However, modern CDC guidelines recommend starting with a combination immunoassay test that simultaneously detects: Antibodies to HIV-1 Antibodies to HIV-2 p24 antigen (a viral protein) The advantage of this combination approach is that it detects p24 antigen during the window period—before antibodies develop—potentially identifying acute infections earlier than antibody-only tests. A negative result on this combination immunoassay effectively rules out recent HIV exposure and no further testing is needed at that time. A positive result requires immediate follow-up with confirmatory testing; do not diagnose HIV based on screening results alone. Confirmatory Testing: Determining the Diagnosis When the initial combination test is positive, the next step is an antibody differentiation immunoassay, which determines which specific antibodies are present. This is essential because HIV-1 and HIV-2 are different viruses requiring different treatment approaches. The differentiation immunoassay produces four possible outcomes: HIV-1 antibody positive, HIV-2 antibody negative: Standard HIV-1 infection. The diagnosis is confirmed. HIV-1 antibody negative, HIV-2 antibody positive: HIV-2 infection, which is less common in most regions and has different treatment implications. Both HIV-1 and HIV-2 antibodies positive: Dual infection or cross-reactivity; nucleic acid testing is needed to clarify. Both antibodies negative or indeterminate: This scenario suggests acute HIV-1 infection during the window period before antibodies have developed. A nucleic acid test (NAT) must be performed to detect viral RNA or proviral DNA and confirm or exclude infection. Alternative Confirmatory Methods The western blot detects specific HIV proteins and was traditionally used for confirmation. However, NAT (including polymerase chain reaction) is increasingly preferred because it can detect virus during the window period when antibodies are absent. Handling Indeterminate Results Occasionally, the confirmatory test yields an indeterminate result, where the antibody pattern doesn't clearly match expected profiles. This typically reflects either an early antibody response (acute infection) or nonspecific reactivity. When western blot results are indeterminate: Collect a second specimen more than one month later Repeat the antibody testing If the second result remains indeterminate, perform nucleic acid testing to resolve the diagnosis This delay exists because early antibody responses may not show the complete pattern of the mature immune response. Post-Exposure Testing Timeline When someone has a potential exposure to HIV (such as through needlestick injury or unprotected sexual contact), testing should follow this schedule: Immediately after exposure: Establish baseline status 6 weeks post-exposure: Allows detection of most infections 3 months post-exposure: Catches delayed seroconversion 6 months post-exposure: Final confirmation This timeline accounts for the window period and ensures that infections are not missed due to early testing. Blood Product Screening Because many infected individuals are unaware of their HIV status, all donor blood and blood products undergo routine screening. This protects transfusion recipients from acquiring HIV through contaminated blood supplies. The same combination immunoassay approach is used, ensuring both antibody and antigen detection. Summary of the Testing Algorithm The modern diagnostic approach prioritizes accuracy and efficiency: screen with a sensitive combination test, differentiate between HIV types, and use nucleic acid testing when antibody patterns are inconclusive. This systematic approach accounts for the window period and ensures that acute infections are not missed while avoiding false positives from nonspecific reactivity.